Logo

ABVC

ABVC BioPharma, Inc.

ABVC

ABVC BioPharma, Inc. • NASDAQ
$2.69 ▲ 0.75% (+0.02)
Market Cap $38.98 M
52w High $5.48
52w Low $0.40
Dividend Yield 0%
P/E -9.61
Volume 29.58K
Outstanding Shares 14.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $795.95K ▲ $1.964M ▼ $-1.247M ▲ -156.607% ▼ $-0.054 ▲ $-1.281M ▲
Q2-2025 $0 $2.295M ▲ $-2.257M ▼ 0% $-0.13 ▼ $-2.099M ▼
Q1-2025 $0 ▼ $693.005K ▲ $-842.075K ▼ 0% ▼ $-0.06 ▼ $-607.275K ▼
Q4-2024 $1.966K ▼ $336.124K ▼ $229.304K ▲ 11.663K% ▲ $0.017 ▲ $-30.09K ▼
Q3-2024 $389.276K $339.033K $-186.561K -47.925% $-0.02 $85.616K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $257.243K ▼ $21.176M ▲ $6.684M ▼ $12.058M ▲
Q2-2025 $1.142M ▲ $16.241M ▲ $6.751M ▼ $7.014M ▲
Q1-2025 $824.62K ▼ $14.876M ▲ $6.919M ▲ $5.404M ▲
Q4-2024 $928.551K ▲ $7.54M ▼ $6.816M ▲ $1.226M ▼
Q3-2024 $840.682K $14.463M $6.484M $8.358M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.247M ▲ $-133.257K ▲ $-1.273M ▼ $1.132M ▼ $-222.415K ▼ $-133.257K ▲
Q2-2025 $-2.257M ▼ $-894.174K ▼ $-665.779K ▼ $1.927M ▲ $316.758K ▲ $-894.174K ▼
Q1-2025 $-944.19K ▼ $-539.833K ▼ $0 $428.756K ▼ $-104.247K ▼ $-539.833K ▼
Q4-2024 $229.304K ▲ $-493.611K ▼ $0 $581.456K ▲ $93.942K ▲ $-493.611K ▼
Q3-2024 $-186.561K $171.724K $0 $-145.393K $27.104K $171.724K

Five-Year Company Overview

Income Statement

Income Statement ABVC looks like a classic clinical‑stage biotech: essentially no product revenue yet and recurring losses as it spends on development and operations. Earnings per share have been negative for years, reflecting the cost of running trials and building the platform without commercial products to offset those expenses. Losses appear to be narrowing somewhat, but the business is still firmly in the “investment and build‑up” phase rather than the “profit and scale” phase. Overall, the income statement tells a story of a company still paying for research, infrastructure, and overhead while it waits for its pipeline to mature.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base and only modest cash reported, suggesting limited financial cushion. Debt appears minimal, which reduces financial leverage risk but also means the company mainly relies on equity funding and partnerships. Equity levels are thin and have fluctuated, and the history of repeated reverse stock splits points to past pressure on the share count and capital structure. Taken together, the balance sheet signals a fragile financial position that is highly dependent on continued external funding to support operations and clinical plans.

Cash Flow

Cash Flow Cash flow patterns fit a pre‑revenue biotech profile: money going out for operations and trials, with little or nothing coming in from product sales. Operating cash flow has been negative in most recent years, and free cash flow mirrors that, since capital spending is small but the company still has ongoing research and corporate costs. This means ABVC likely needs periodic capital raises, licensing payments, or other external sources to keep funding its programs. Its ability to time those inflows against cash burn is a key uncertainty and a central financial risk.

Competitive Edge

Competitive Edge ABVC is trying to carve out a differentiated niche by focusing on botanical‑based drugs and a vertically integrated supply chain, rather than traditional synthetic molecules alone. Its strategy combines control of plant cultivation, manufacturing, and clinical development, which could offer quality, cost, and branding advantages if it can execute. A growing patent portfolio and a diversified pipeline across depression, ADHD, eye surgery, and oncology add some breadth and help avoid reliance on a single asset. However, the company still competes in a crowded biotech environment with much larger, better‑funded rivals, and it has not yet proven its approach in the marketplace.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of ABVC’s story. The company is advancing several botanical‑based drug candidates and a distinctive eye‑surgery device, each aimed at significant medical needs and backed by patents extending well into the future. Its model of in‑licensing from leading research institutions lets it tap strong science without bearing the full cost of early discovery, while the planned “gigafactories” and vertical farming aim to secure a steady, high‑quality supply of plant material. The flip side is execution risk: clinical trials must succeed, regulators must approve the products, and the company must actually build and run its advanced farming and manufacturing facilities, all of which require capital, time, and operational discipline.

Summary

Overall, ABVC is an early‑stage, high‑uncertainty biotech with a distinctive focus on botanical therapeutics and supply‑chain control, but with very limited current financial strength. The company’s value proposition rests almost entirely on the future success of its pipeline and its ability to turn a novel, integrated model into real commercial products. Its financials show no meaningful revenue and ongoing cash consumption, implying continued reliance on outside capital and partnerships. If its key programs and vertical integration plans progress well, the business profile could change significantly; if they stall or funding tightens, the current thin balance sheet leaves limited margin for setbacks.